Skip to main content
NGL Fine Chem Ltd. logo

NGL Fine Chem Ltd. — Investor Relations & Filings

Ticker · NGLFINE ISIN · INE887E01022 LEI · 335800X5TUU2OAV19X07 BSE.NS Manufacturing
Open in API
Filings indexed 308 across all filing types
Latest filing 2025-05-26 Regulatory Filings
Country IN India
Listing BSE.NS NGLFINE

About NGL Fine Chem Ltd.

https://www.nglfinechem.com

NGL Fine Chem Ltd. specializes in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates for both veterinary and human healthcare sectors. The company focuses on high-quality chemical synthesis, producing a diverse range of products including anthelmintics, ectoparasiticides, and specialty chemicals. Key products in its portfolio include Nitroxynil, Closantel, Oxyclozanide, and Triclabendazole. Operating with Good Manufacturing Practice (GMP) standards, the firm serves a global clientele, providing customized manufacturing solutions and maintaining a strong emphasis on research and development to enhance process efficiency and product quality. Its technical expertise lies in complex chemical reactions and large-scale production of niche pharmaceutical components.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Regulatory Filings
2025-05-26 English
Investor Presentation
Regulatory Filings
2025-05-23 English
Record Date
Regulatory Filings
2025-05-22 English
Appointment
Board/Management Information Classification · 95% confidence The document text primarily details the appointment and re-appointment of various auditors and consulting firms, including secretarial auditors, internal auditors, and cost accountants, along with their profiles and terms of appointment. There is no indication of financial statements, earnings data, voting results, or regulatory certifications. The content focuses on management and board-related changes, specifically appointments of key audit and consulting personnel. The document length is 3424 characters, which is relatively short but contains substantive information about management appointments rather than just an announcement. Therefore, the document best fits the category of Board/Management Information (MANG).
2025-05-22 English
Appointment
Board/Management Information Classification · 100% confidence The document text primarily details appointments of new directors and changes in the board of directors, including terms of appointment, brief profiles, and related disclosures. There is no indication of financial data, audit information, or other report types. The content fits the category of announcements related to changes in the company's board or senior management.
2025-05-22 English
Appointment
Board/Management Information Classification · 95% confidence The document text primarily contains detailed information about appointments of directors and changes in the company's board of directors, including terms of appointment, brief profiles, and affirmations regarding regulatory compliance (e.g., SEBI orders). There is no indication of financial data, audit information, or other report types. The content fits the description of announcements related to changes in the company's board or senior management. Therefore, the document is best classified under Board/Management Information (MANG). The document length (5616 characters) supports that this is a substantive announcement rather than a brief notice or report publication announcement.
2025-05-22 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.